RxDoctor Payments Data

Claire Sullivan, MD

Cardiovascular Disease · Cleveland, OHNPI 1558688580

Payments from drug & device makers

$2,294in general payments, 2019–2025

Across 107 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$455
  • Amgen$376
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$272
  • AstraZeneca$185
  • Novo Nordisk$124
  • Astellas Pharma US Inc$123
  • plus $759 from 21 others

What the payments were for

  • Food & beverage$2,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,294 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$35,602
Medicare patients
211
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab321$206,843
EliquisApixaban155$138,840
JardianceEmpagliflozin55$74,424
Praluent PenAlirocumab70$47,440
OzempicSemaglutide42$41,330
MounjaroTirzepatide32$33,928
EntrestoSacubitril/Valsartan35$32,267
VascepaIcosapent Ethyl30$22,246
XareltoRivaroxaban14$16,076
NexletolBempedoic Acid14$14,087
Dofetilide13$3,418
Rosuvastatin Calcium139$1,647
Ezetimibe54$1,548
Metoprolol Succinate112$1,477
Nebivolol Hcl24$1,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$138,840155 claims
Boehringer IngelheimJardiance$18$74,42455 claims
Novo NordiskOzempic$124$41,33042 claims
NovartisEntresto$455$32,26735 claims
Johnson & JohnsonXarelto$24$16,07614 claims
Esperion Therapeutics, Inc.Nexletol$77$14,08714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →